Topic 153
biodistribution delivery therapeutic antibody vivo bioengineering anti nanoparticles mouse therapy uptake mice blood nanoparticle intravenous efficacy targeting liver safety treatment administration drug tumor dose antibodies murine inflammation effective targeted organs significant acute fusion monoclonal cause toxicity cancer clinical injection barrier bbb therapies spliced doses expressing f8 promising engineered preclinical against fibronectin mab vitro immunomodulatory improved cells eda transgenic humanized treating accumulation target chemotherapeutic models serum after kidney necrosis agent burden transcytosis route antigen administered alternatively conjugated ex green vectors lung development vascular morbidity invasive selectively myocardial cell spleen patients agents nanomolar bearing potential disease recombinant injury tumors established treated body
55 items. Top items listed below.